TWC
OVID icon

TD Waterhouse Canada’s Ovid Therapeutics OVID Stock Holding History

TD Waterhouse Canada’s Portfolio OVID Stock Details OVID Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$65 Hold
30
– – ﹤0.01% 2245
2025
Q4 		$49 Hold
30
– – ﹤0.01% 1998
2025
Q3 		$41 Hold
30
– – ﹤0.01% 2020
2025
Q2 		$10 Hold
30
– – ﹤0.01% 1970
2025
Q1 		$9 Hold
30
– – ﹤0.01% 1927
2024
Q4 		$28 Hold
30
– – ﹤0.01% 1930
2024
Q3 		$34 Buy
+30
New +$31 ﹤0.01% 1854

Other funds holding OVID

RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
AAA
Affinity Asset Advisors New York $1.94B AUM 374.45% 1-Year Est. Return
EAM
Eventide Asset Management Boston, Massachusetts $6.05B AUM 76.64% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $77.1B AUM 42.89% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
ACM
ADAR1 Capital Management Austin, Texas $1.7B AUM 340.85% 1-Year Est. Return
SVCM
Saturn V Capital Management Austin, Texas $552M AUM 551.78% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return

TD Waterhouse Canada's OVID Position: Q1 2026 in Review

TD Waterhouse Canada held its Ovid Therapeutics (OVID) position steady in Q1 2026 at 30 shares worth $65. The position accounts for ﹤0.01% of the portfolio, ranked #2245.

TD Waterhouse Canada first reported a position in OVID in Q3 2024 and has held it in 7 quarters since. 103 funds tracked by Wall St. Rank hold OVID as of Q1 2026.

  • TD Waterhouse Canada held 30 shares of Ovid Therapeutics worth $65 as of Q1 2026.
  • TD Waterhouse Canada left its Ovid Therapeutics share count unchanged in Q1 2026.
  • Ovid Therapeutics made up ﹤0.01% of TD Waterhouse Canada's portfolio in Q1 2026, its #2245 holding.
  • TD Waterhouse Canada first reported a position in Ovid Therapeutics in Q3 2024 and has held it in 7 quarters since.
  • 103 funds tracked by Wall St. Rank held Ovid Therapeutics as of Q1 2026.

Based on TD Waterhouse Canada's 13F filing for Q1 2026, filed 12 May 2026.